Tag Archives: Disability Assessment for Dementia-DAD

Bapineuzumab Trials Results in Mild-to-Moderate Alzheimer’s Disease (New England Journal of Medicine)

Summary Bapineuzumab is an anti-amyloid-beta monoclonal antibody, which had shown promise for the treatment of Alzheimer’s Disease. Two double-blind, randomised, placebo-controlled, phase 3 trials have been conducted, involving 2204 patients with mild-to-moderate Alzheimer’s disease. One trial involved 1121 carriers of … Continue reading

Posted in For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Behavioural Variant Frontotemporal Dementia: Systematic Review (Biomed Research International)

Summary This systematic review examines the functional profile of patients with behavioural variant frontotemporal dementia (bvFTD). Full Text Link Reference Lima-Silva, TB. Bahia, VS. Nitrini, R. [et al]. (2013). Functional status in behavioral variant frontotemporal dementia: a systematic review. Biomed … Continue reading

Posted in For Doctors (mostly), For Researchers (mostly), International, Systematic Reviews | Tagged , , , , , , , , , , , , , , , , , , , , , | Leave a comment